HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Growth in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 62,738 shares, a growth of 457.9% from the November 30th total of 11,245 shares. Based on an average trading volume of 50,488 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.1% of the shares of the company are short sold. Currently, 4.1% of the shares of the company are short sold. Based on an average trading volume of 50,488 shares, the days-to-cover ratio is currently 1.2 days.

HCW Biologics Stock Performance

HCWB traded down $0.07 during trading on Friday, reaching $1.42. 37,809 shares of the company traded hands, compared to its average volume of 730,283. The company has a market cap of $3.84 million, a P/E ratio of -0.12 and a beta of 0.66. HCW Biologics has a 12-month low of $1.34 and a 12-month high of $41.20. The firm has a fifty day simple moving average of $2.59 and a 200 day simple moving average of $3.80.

HCW Biologics (NASDAQ:HCWB) last issued its quarterly earnings data on Friday, November 14th. The company reported ($2.02) earnings per share for the quarter, missing analysts’ consensus estimates of $1.58 by ($3.60). The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $7.00 million.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 2.96% of the company’s stock.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.